Agios Pharmaceuticals (NASDAQ:AGIO) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Agios Pharmaceuticals (NASDAQ:AGIO) issued its earnings results on Thursday. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05), Zacks reports. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock traded down $0.49 on Thursday, reaching $33.53. 61,899 shares of the company were exchanged, compared to its average volume of 740,619. The company’s 50-day moving average is $34.45 and its two-hundred day moving average is $43.14. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 2.96 and a beta of 0.88. Agios Pharmaceuticals has a 1-year low of $26.50 and a 1-year high of $62.58.

Analyst Upgrades and Downgrades

AGIO has been the subject of several analyst reports. Scotiabank upped their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Royal Bank of Canada boosted their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Finally, StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $56.33.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.